Abstract Introduction Low female sexual desire (HSDD) is one of the most common sexual complaints in women. As a result, many women suffer from sexual dissatisfaction and related distress, which often negatively interferes with their quality of life. Little is known about the underlying biological mechanism of low desire, but it is conceivable that sexual functions are the result of an interaction between biological, psychological, and relational factors, for which neurological and hormonal central and peripheral processes are involved. Women's sexual desires naturally fluctuate over the years and commonly coincide with the beginning or end of a relationship, health status, medication use, and/or major life events. The treatment approach for females with low sexual desire is aimed at the many causes behind this condition. Recommendations may include sex education, counseling, and sometimes medication and hormone therapy mainly for women who go through menopause or post-menopause. So far no medical therapy for HSDD is available in Europe. While some women movements, such as “right to desire” wish to support the development of drugs for HSDD and reduce the distress associated with HSDD, others are against what they call “the pathologizing of variation in the population” and drug developments. Objective The aim of this survey was to find the prevalence of HSDD among young, premenopausal, social media active women and their willingness to receive medical therapy. Methods A social media survey has been conducted among women between 18 and 50 years old who are regularly using social media apps, in Israel. A country with a mix of cultures, religions, and personal social backgrounds. Women were asked about their sexual desire, current experience with a reduction of their desire for more than 6 months, and the presence of distress. Women who suffer from low desire have been asked about their willingness to receive medical treatment for this condition. Results 4079 women observed the survey but only 1493 (36.6%) answered the questions. 42% (624) stated that they suffer from a decline in desire for a period longer than 6 months, while 49% (727) said they did not suffer from a decline in sexual desire. 9% (142) of the women answered that they didn’t know. On the question: “would you be interested in drug treatment ‘that ’ was asked only to the women who reported a decline in sexual desire, 22% (138) were interested in drug treatment, 40% (249) were not interested in drug treatment, 12% (75)said they don’t know and 26% (162) stated that their wiliness to use a drug for HSDD depended on the risk and benefits. Conclusions HSDD is prevalent even among premenopausal women in a multicultural country. Despite the multifactorial factors involved in the etiology of HSDD, almost half of the women have an interest in using a safe medication for HSDD. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Freya, Besins, Ohhmed.
Read full abstract